PANCREATIC CANCER ACTION NETWORK

The Pancreatic Cancer Action Network Increases Biomarker-Driven Clinical Trial Matching Capabilities by Nearly 300% with GenomOncology

OVERVIEW

In an effort to create a world in which all patients with pancreatic cancer will thrive, the Pancreatic Cancer Action Network (PanCAN) is dedicated to matching patients to the best treatment opportunities. PanCAN takes bold action to improve the lives of everyone impacted by pancreatic cancer by advancing scientific research, building community, sharing knowledge, and advocating for patients.

THE PROBLEM

PanCAN recommends clinical trials, including those targeted to a tumor's biology, to pancreatic cancer patients at diagnosis, as well as at every treatment decision. However, as the amount of data continues to increase in the field of precision medicine, PanCAN needed a toolset that navigated through and transformed this evolving data in order to streamline biomarker-driven searches and serve more patients through PanCAN Patient Services.

> "Prior to utilizing GenomOncology's clinical trial matching solution, we ran all biomarker-driven clinical trial searches manually. This manual process was tedious and time-consuming, and resulted in fewer patient matches per week. When we implemented GenomOncology's solution, we were able to expand our searches significantly. We now have the ability to search multiple biomarkers at once, as well as identify wild-type and partial matches, which was virtually impossible before. The combination of improved efficiency and accuracy of the biomarker-driven searches has exponentially improved our matching capabilities, ultimately helping us serve more patients."

- Tori Larrick, Manager, Scientific & Medical Affairs

THE SOLUTION

After considering various clinical trial matching products, including changes to their existing proprietary matching system, PanCAN decided to implement GenomOncology's clinical trial matching solution. PanCAN chose to utilize GenomOncology due to their overall industry knowledge and expertise, as well as the breadth of clinical trial curation available within the solution. This level of detail, including biomarker status, eligibility criteria, and phase enables the PanCAN team to match more patients to relevant biomarker-driven clinical trials at a more efficient rate.

RESULTS

50%
total reduction in time spent on biomarker trial searches

24-hour
turnaround time for trial results, a 200% improvement in turnaround time

15-20
weekly biomarker-driven searches, previously team could only handle max 5 searches

25+
team members are able to do biomarker-driven trial searches, previously 1-2 team members

FUTURE CAPABILITIES

In 2021, PanCAN will implement GenomOncology's newest solution, Precision Decision, to further enhance PanCAN's Patient Services. PanCAN will now have access to:

- Enhanced clinical trial and targeted therapy matching.
- Integration with their patient tracking system to reduce manual entry of patient demographic data.
- Improved searches based on the patient's prior intervention history, including chemotherapy, surgery, radiation, targeted therapy administration, or if they have participated in other clinical trials.
- Advanced analytics to better understand patient recommendations over a period of time.